I
Inotek Pharmaceuticals
Inotek Pharmaceuticals develops drug candidates to address significant diseases of the eye
About Inotek Pharmaceuticals
Inotek Pharmaceuticals Corporation was a clinical-stage biopharmaceutical company, founded in 1996 by Andrew Salzman, with its headquarters in Lexington, Massachusetts. The company concentrated its efforts on the discovery, development, and commercialization of treatments for serious ocular diseases, particularly glaucoma. Its business model was centered on advancing its product candidates through rigorous human clinical trials, a process that involved substantial investment in research and development. The company was publicly traded on the NASDAQ under the ticker ITEK.
The primary asset in Inotek's pipeline was trabodenoson, a first-in-class selective adenosine mimetic. This compound was designed to lower intraocular pressure (IOP), a key factor in glaucoma, by restoring the eye's natural fluid drainage system through the trabecular meshwork. Trabodenoson was developed as both a monotherapy eye drop and in a fixed-dose combination with latanoprost, a standard glaucoma treatment. The development program for trabodenoson progressed through Phase 1, 2, and 3 clinical trials. While early and mid-stage trials showed promising results in IOP reduction with good tolerability, the pivotal Phase 3 MATRx-1 monotherapy trial and a subsequent Phase 2 trial of the fixed-dose combination failed to meet their primary efficacy endpoints, showing only marginal improvement over existing treatments or placebo.
Following the disappointing clinical trial outcomes in 2017, Inotek began exploring strategic alternatives to maximize shareholder value. This process culminated in a definitive merger agreement with Rocket Pharmaceuticals Ltd., a private, US-based gene therapy company. The transaction, which closed in January 2018, was a reverse merger that saw the combined entity retain the Rocket Pharmaceuticals name and focus on developing gene therapies for rare diseases. Inotek shareholders retained approximately 19% of the new company, with the deal effectively marking the end of Inotek's operations as an independent entity focused on ophthalmology. The merger provided Rocket with a Nasdaq listing and access to Inotek's remaining cash reserves.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Open positions
- None listed
- Dealroom signal
- 22.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Sep 2017 | $0 | — | Rocket Pharmaceuticals | — |
| IPO✓Exit | Feb 2015 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Inotek Pharmaceuticals is 190 monthly website visits, down 84.2% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Inotek Pharmaceuticals in the Lexington ecosystem
The Inotek Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
MedImmune Ventures
Rho Ventures
La Caisse
Series B and later3 investors entered at this stage
- DBDevon Park BioVentures
Pitango Venture Capital
Rho Capital Partners
Other known investors2 additional known investors
Rocket Pharmaceuticals- CCCare Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Inotek Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Inotek Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








